RGMP   $0.2  -20.00% Market Closed

Regnum Corp
Last Events:

2023-07-18 Signal in MACD changed from bullish to bearish. Oscillator MACD is in the negative territory it crossed the signal line from the top and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: main and signal line crossing.

2023-05-19 Signal in MACD changed from bullish weakening to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-05-17 Trend pattern changed from не определен to расходящийся клин с наклоном вниз.

2023-05-17 Signal in Stochastic changed from не определен to bearish. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: entry into the oversold zone.

2023-05-17 Signal in MACD changed from не определен to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: up-crossing the middle level.

2023-05-17 Signal in RSI changed from не определен to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-05-17 Signal in EMA100 changed from не определен to n/a.

2023-05-17 Signal in EMA50 changed from не определен to bearish reversal. 2023-04-24 the price crossed down the moving average line and formed a short-term downside trend.


Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell -
rsi Sell Sell -
macd - Sell -
stoch - Sell -
ma20 ActivelyBuy - -
ma50 - Sell -
ma100 Sell Sell -
ISIN US75915R1068
ceo Ms. Anne Kirby
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.